U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H24N6
Molecular Weight 432.5197
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIRANSERTIB

SMILES

NC1=NC=CC=C1C2=NC3=CC=C(N=C3N2C4=CC=C(C=C4)C5(N)CCC5)C6=CC=CC=C6

InChI

InChIKey=HNFMVVHMKGFCMB-UHFFFAOYSA-N
InChI=1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)

HIDE SMILES / InChI

Molecular Formula C27H24N6
Molecular Weight 432.5197
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Miransertib (ARQ 092) is a selective, pan-AKT (protein kinase B) inhibitor that potently inhibits AKT1, 2 and 3 isoforms. Miransertib binds inactive AKT, preventing membrane localization and subsequent AKT activation, and binds active AKT, resulting in direct inhibition. Miransertib participates in Phase 1/2 of clinical trials to treat patients at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS). In addition, the drug is involved in the phase I trial in patients with lymphoma, endometrial cancer, and AKT1 E17K mutations. Recently was shown that miransertib could be an excellent lead compound for the development of new oral drug therapy for visceral and cutaneous leishmaniasis.

Approval Year

Targets

Targets

PubMed

PubMed

TitleDatePubMed
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
2017 Feb

Sample Use Guides

ARQ 092 orally at 15 mg/m2 QD for the first 3 cycles on a 28 day schedule
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:49:46 GMT 2023
Edited
by admin
on Sat Dec 16 01:49:46 GMT 2023
Record UNII
T1DQI1B52Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIRANSERTIB
INN  
USAN   INN  
Official Name English
ARQ-092
Code English
Miransertib [WHO-DD]
Common Name English
2-PYRIDINAMINE, 3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO(4,5-B)PYRIDIN-2-YL)-
Systematic Name English
3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3H-IMIDAZO(4,5-B)PYRIDIN-2-YL)-2-PYRIDINAMINE
Systematic Name English
ARQ092
Code English
MIRANSERTIB [USAN]
USAN  
Common Name English
3-(3-(4-(1-AMINOCYCLOBUTYL)PHENYL)-5-PHENYL-3HIMIDAZO(4,5-B)PYRIDIN-2-YL)PYRIDIN-2-AMINE
Systematic Name English
miransertib [INN]
Common Name English
ARQ092 FREE BASE
Code English
ARQ 092 [WHO-DD]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 497115
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
EU-Orphan Drug EU/3/18/1997
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
Code System Code Type Description
CAS
1313881-70-7
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545422
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
DRUG BANK
DB14982
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
FDA UNII
T1DQI1B52Y
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
NCI_THESAURUS
C99172
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
USAN
FG-205
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
PUBCHEM
53262401
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
SMS_ID
100000176018
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
INN
10490
Created by admin on Sat Dec 16 01:49:46 GMT 2023 , Edited by admin on Sat Dec 16 01:49:46 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY